South Korea vows support for biopharmaceutical, auto sectors over US tariffs

South Korea's government announced additional support measures for key export industries, including biopharmaceutical and auto sectors, in anticipation of potential tariffs from the U.S. The government will prepare specific measures for biopharmaceutical companies once details of U.S. tariffs are available, noting that 16% of South Korea's $9.59 billion in pharmaceutical exports went to the United States in 2024. These actions supplement previously announced support packages and ongoing trade talks with Washington aimed at securing tariff exemptions by early July.

Analysis

The South Korean government is proactively addressing potential economic headwinds from anticipated U.S. tariffs by pledging further support for key export sectors, notably biopharmaceuticals and autos. This response follows U.S. President Trump's executive order aimed at bolstering domestic pharmaceutical manufacturing and initiating probes into pharmaceutical imports, signaling a protectionist shift. While South Korea's pharmaceutical exports, valued at $9.59 billion in 2024, constitute only 1.4% of its total exports, the U.S. market's significance is underscored by its 16% share of these exports. The government's commitment to new support measures, contingent on the specifics of U.S. tariffs, complements earlier aid packages for automakers, chipmakers, and steel manufacturers. Seoul is concurrently engaged in technical discussions with Washington, aiming to secure tariff exemptions through a trade package by early July. Despite unexpectedly resilient overall exports last month, driven by strong semiconductor demand, emerging signs indicate that global trade tensions, reflected in the cautious market sentiment, are beginning to affect South Korea's crucial auto sector.

Key Decisions for Investors

• Investors should closely monitor the outcome of the U.S.-South Korea trade negotiations by early July and the specifics of any U.S. tariffs, particularly on biopharmaceuticals, as these will directly impact companies with significant U.S. market exposure.
• It is prudent to assess holdings in South Korean biopharmaceutical and automotive companies, especially those with substantial revenue derived from the United States, considering potential margin pressures or market share shifts due to tariffs, even with prospective government aid.
• Consider the potential mitigating impact of South Korean government support measures on affected industries, but maintain a cautious stance on sectors heavily reliant on U.S. exports until greater clarity on tariff implementations and exemptions is achieved.